Loading stock data…
$37.45+1.18 (+3.24%)
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Edgewise Therapeutics, Inc. in the Healthcare sector is trading at $37.64 with a market capitalization of $4.8B. Wall Street consensus targets $52.62 (13 analysts), implying a +39.8% move over the next 12 months. The stock is currently 22% below its 52-week high of $48.51, remaining 6.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$61.94M↓ | -$54.12M↑ | -$55.98M↓ | -$46.86M↓ | -$42.61M |
| Net Income | -$57.33M↓ | -$49.01M↑ | -$50.22M↓ | -$40.67M↓ | -$36.12M |
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clini...